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Analysis of the Bactericidal Activity of Antiserum Raised Against the N-Terminal Half of an 85- 
kilodalton Outer Membrane Protein of Neisseria meningitidis (54pp.)
Director; Ralph C. Judd  ̂ , /
The closely related pathogenic Neisseria species, N. meningitidis and N. gonorrhoeae, infect an 
estimated 500,000 and 250 million people annually worldwide, respectively. Development of 
effective vaccines to prevent infection has proven difficult. A quadrivalent polysaccharide 
vaccine is currently available against N. meningitidis^ however, this vaccine does not confer 
protection against all major pathogenic serogroups. Furthermore, because the current 
meningococcal vaccine is not based on a protein antigen, it is poor at inducing immunological 
memory. There is currently no vaccine available against gonorrhea. Efforts to develop such a 
vaccine have been hampered by the lack of an appropriate animal model and tremendous 
antigenic- and phase variation exhibited by most major gonococcal outer membrane proteins. 
Therefore, attractive vaccine candidates would include less major protein molecules that are 
universally and constitutively expressed by pathogenic Neisseria.
A  recently discovered 85-kilodalton outer membrane protein (Omp85) of Neisseria appears to 
be such a vaccine candidate. Omp85 is universally expressed by Neisseria, and its expression is 
highly conserved within species. Furthermore, Omp85 homologues in other pathogenic bacteria 
were shown to be capable of inducing protective immunity. The vaccine potential of Omp85 was 
evaluated in this project by analyzing the bactericidal activity of rabbit antiserum raised against 
the N-terminal 445 amino acids, approximately half entire length, of meningococcal Omp85 
(N445mcOmp85). The N-terminal half of Omp85 was the focus of this study because it was 
previously shown that the entire Omp85 molecule is difficult to express in E. coli, and 
systematically evaluating different fragments of Omp85 will allow for pinpointing of a putative 
bactericidal-elicitmg epitope.
Bactericidal assay results indicated that anti- N445mcOmp85 rabbit serum was unable to promote 
strong, specific complement-mediated killing of Neisseria. This may be due to the paucity of 
Omp85 molecules on the bacterial surface, which would decrease the likelihood of complement 
cascade initiation by antigen cross-linking. However, since the function of Omp85 is still 
unknown, it is possible that antibodies against Omp85 may disrupt an essential function or 
prevent cell adhesion. Thus, further studies to examine the vaccine potential of Omp85 are 
warranted.
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Introduction
Prevention and control of diseases caused by pathogenic Neisseria species. Neisseria 
gonorrhoeae and Neisseria meningitidis, have been hampered by lack of an effective vaccine. 
Development of a vaccine against these species has been difficult since a conserved, non­
variable, sufficiently immunogenic protein molecule expressed by all strains within a species has 
yet to be identified. The goal of this project was to evaluate the vaccine potential of a recently 
discovered 85-kilodalton (kDa) Neisseria outer membrane protein (Omp85). Omp85 is 
invariantly expressed by all N. gonorrhoeae and N. meningitidis strains studied thus far. In 
addition, Omp85 is similar at the amino acid level to bacterial outer membrane proteins known to 
elicit protective immunity. Therefore, it is possible that an Omp85-based vaccine would confer 
protective immunity against all strains of N. gonorrhoeae and N. meningitidis.
This project primarily focused on the vaccine potential of meningococcal Omp85. Experiments 
involving viable meningococci were performed using a non-pathogenic, non-encapsulated strain; 
however, since the purpose of this work was to evaluate the vaccine potential of Omp85 against 
pathogenic Neisseria, encapsulated N. meningitidis would be used in assays if warranted by 
results from the present experiments. Since meningococcal Omp85 is nearly identical to 
gonococcal Omp85 at the amino acid level, several strains of N. gonorrhoeae were also used to 
evaluate the vaccine potential of meningococcal Omp85. The high identity between 
meningococcal- and gonococcal Omp85 would be advantageous to any prospective Omp85-based 
vaccine, since such a vaccine could potentially confer protection against both meningococcemia 
and gonorrhea.
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1-1. Neisseria meningitidis infection
N. meningitidis is a human pathogen that causes fulminant meningococcal sepsis and 
meningococcal meningitis. Fulminant meningococcal sepsis results from proliferation of N. 
meningitidis in the blood and release of endotoxins; symptoms include fever, chills, muscle aches, 
hemorrhagic skin rash, diffuse intravascular coagulation, and shock. Death may occur within the 
first few hours of disease, resulting in mortality rates of up to 80% (28). Meningococcal 
meningitis results when N. meningitidis invades the meninges; symptoms include skin rash, fever, 
headache, photophobia, irritability, vomiting, and neck stiffness. Death occurs in up to 5% of 
patients due to intracranial pressure (28). Those that recover may suffer from deafness, mental 
retardation, or seizures (28).
N. meningitidis occurs naturally in the nose of approximately 10% of the population (28). 
However, 90% of these commensal strains are nonpathogenic. Disease occurs when the blood is 
accessed by the oropharynx by encapsulated pathogenic strains of N. meningitidis, most of which 
belong to one of the following serogroups; A, B, C, W-135, or Y. In industrialized nations, 
disease occurrence is 1 to 3 per 100,000; this number increases to 10 to 25 per 100,000 in third 
world countries (28). Those most susceptible to disease include young children, immune- 
compromised individuals, and those subject to abject social conditions. Crowding facilitates 
outbreaks of disease, since meningococci are transmitted via direct contact and respiratory 
droplets up to a distance of one meter. Consequently, outbreaks are prone to occur in populations 
of military personnel, school children, and jail inmates.
Early administration of penicillin or cephalosporins is effective at treating menmgocccal 
infection. However, diagnosis during early stages of infection is difficult since early symptoms 
are ambiguous; fever, chills, muscles aches, and vomiting are symptoms common to non- 
meningococcal bacterial and viral infections. As a result, treatment may not be initiated until
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later in infection, where the likelihood of a complete recovery is decreased. Emphasis must, 
therefore, be placed on disease prevention.
1-2. Neisseria gonorrhoeae infection
Neisseria gonorrhoeae is the causative agent of gonorrhea, a leading cause of urethritis, 
cervicitis, and pelvic inflammatory disease (PID) in the United States. Occurrence of this 
sexually transmitted disease is known to date back to 2637 BC, when the Chinese emperor Huang 
Ti described venereal urethral discharges among his people (23). Symptoms of the disease were 
also described by Hippocrates in 400 BC (23). Gonorrhea continues to persist as a prominent 
sexually transmitted disease despite effective antibiotic treatments, including penicillin and 
tetracycline. This may be partially attributed to the fact that up to 40% of infected men and 80% 
of infected women are asymptomatic for disease (23). Consequently, although effective 
treatments are available, many infected individuals do not receive treatment. These 
asymptomatic individuals may serve as carriers who spread disease,
N. gonorrhoeae is specifically adapted for survival in the human urogenital tract. Infection is 
initiated when the bacterium colonizes the apical side of nonciliated epithelial cells (19). The 
organism then travels transcellularly to exit through the basolateral side of the host cell, resulting 
in infection of the basement membrane (19). Symptoms of genital gonococcal infection are a 
result of damage to the epithelial cells caused by transcellular passage of the bacterium and 
inflammation at the infected site. In men, symptoms of uncomplicated genital gonococcal 
infection include urethritis, dysuria, and discharge of purulent exudates (23). Local spread of 
infection leads to prostatitis, seminal vesiculitis, epididymitis, and inguinal lymphadenitis (23). 
Chronic inflammation can lead to blockage of the sperm ducts, resulting in sterility (11). In 
women, uncomplicated gonococcal infection primarily affects the columnar epithelium of the 
endocervix, resulting in cervicitis. (23). Symptoms include abnormal or increased vaginal
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discharge, abnormal uterine bleeding, dysuria, and frequent urinations (23). Ascending 
gonococcal infection causes acute salpingitis and pelvic inflammatory disease (PID) (23). 
Chronic scarring of the fallopian tubes may also result, leading to sterility (11), Furthermore, 
destruction of ciliated cells lining the fallopian tube can lead to ectopic pregnancy (11).
Disseminated gonococcal infection (DGI) results from exit of the organism through the 
basolateral side of epithelial cells and subsequent entry into the bloodstream. DGI is 
characterized by several symptoms, including gonococcal meningitis, gonococcal endocarditis, 
infectious arthritis, and dermatitis. The latter is manifested by petechiae, pustules, hemorrhagic 
lesions, or ulcerative lesions (23). Non-specific symptoms of DGI include fever, chills, malaise, 
liver function abnormalities, and leukocytosis (23). N. gonorrhoeae also infects the 
oropharyngeal and ophthalmic regions (11). The latter is most commonly acquired by newborns 
through infected birth canals (ophthalmia neonatorum) (11).
1-3. Vaccines currently available against N. meningitidis and N. gonorrhoeae
Development of an effective vaccine against pathogenic Neisseria has proven difficult. A 
quadrivalent polysaccharide vaccine is currently available against N. meningitidis serogroups A, 
C, W-135, and Y. However, the efficacy of this vaccine is limited by several factors. First, 
because the vaccine is not based on a protein antigen, it is poor at inducing immunological 
memory. Second, it is not very effective in infants. Last, the vaccine is ineffective against 
serogroup B, which causes one-third of all meningococcal infections in the United States and 
Europe (28). An effective polysaccharide vaccine against serogroup B will not likely be 
developed since its capsular polysaccharide is very similar to neuronal cell adhesion molecule, 
thus posing a risk of autoimmunity (28). Furthermore, serogroup B polysaccharide capsule 
induces a weak antibody response during natural infection.
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There is currently no vaccine available against N. gonorrhoeae. Efforts to develop such a vaccine 
have been hampered by the fact that there is no animal model for gonococcal infection, and most 
major outer membrane proteins of N. gonorrhoeae exhibit tremendous antigenic- and phase 
variation. Therefore, development of a vaccine against both N. gonorrhoeae and N. meningitidis 
would be benefited by less prominent outer membrane protein antigens that are universally and 
conservatively expressed by Neisseria, and are capable of inducing protective immunity. 
Preliminary evidence suggests that Omp85 may be such an antigen.
1-4. Omp85
Manning et al. discovered Omp85 in the mid-1990’s by screening a genomic library with serum 
raised against isolated gonoccocal outer membrane proteins (17). Omp85 was found to contain a 
putative signal peptide and a carboxyl-terminal phenylalanine residue, both of which are 
characteristic of outer membrane proteins ( 17). Western blot analysis showed that rabbit serum 
raised against gonococcal Omp85 cross-reacts with meningococcal whole cell lysates, indicating 
that Omp85 is also expressed by N. meningitidis (17). Presence of the Omp85 gene in N. 
meningitidis was later confirmed by genome comparison and DNA sequencing (13). The 
following preliminary evidence suggests that Omp85 may be used to develop an effective vaccine 
against N. meningitidis'. 1) Omp85 is highly similar to outer membrane proteins that have been 
shown to induce protective immunity, 2) Omp85 is universally and constitutively expressed in an 
invariant manner by all N. meningitidis strains studied to date, and 3) Omp85 is a protein antigen.
Otnp85 is highly similar to outer membrane proteins that induce protective immunity.
A GenBank database search revealed that Omp85 is 61% similar to D-15-Ag of Haemophilus 
influenzae and Oma87 of Pasteurella multocida (17). It has been previously shown that D-15-Ag 
and Oma87 are capable of inducing protective immunity (8,16,18,26). Loosmore et al., 
demonstrated protective immunity elicited by D-15-Ag when 10 out of 13 rat pups passively
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immunized with anti-D-15 rabbit serum were protected against H. influenzae challenge (16). 
Similar findings were reported by Thomas et aL, who demonstrated that preabsorbing a 
suspension o f H. influenzae with anti-D-15 antibodies prevented the organism from causing 
disease in rats (26). Protective immunity elicited by Oma87 was demonstrated by Ruffolo and 
Adler, who showed that anti-Oma87 serum protected mice from P. multocida challenge (24).
Omp85 is universally and constitutively expressed in an invariant manner by N. meningitidis and 
N. gonorrhoeae.
Western Blot analysis revealed that Omp85 is expressed by all strains of N. meningitidis and N. 
gonorrhoeae studied to date (13). DNA sequence analysis showed that Omp85 is identical in all 
intraspecies strains (13). Interspecies homology is also high; at the amino acid level, 
meningococcal- and gonococcal Omp85 are 95% identical and 98% similar (17).
Meningococcal- and gonococcal Omp85 are also nearly identical at the nucleic acid level, with 
only one region of variation occurring between base pairs 720 and 752.
Omp85 is a protein antigen.
Shortcomings of the current capsular polysaccharide meningococcal vaccine are outlined above. 
Since Omp85 is a protein antigen, it is not subject to the limitations of a polysaccharide antigen. 
Thus, an Omp85-based vaccine may potentially induce immunological memory, confer protection 
upon infants, and have effectiveness against N. meningitidis serogroup B.
The function of Omp85 is currently unknown. However, the following functions have been 
hypothesized:
1) Omp85 may be involved in mucosal colonization by Neisseria. All species of Neisseria 
colonize mucosal surfaces (17). Since Omp85 is expressed by all pathogenic and non-pathogenic
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Neisseria species studied thus far, it is possible that Omp85 may play a role in mucosal 
colonization.
2) Omp85 may be involved in protein transport. GenBank database search revealed 35% 
similarity between Omp85 and a chloroplast outer membrane protein (IAP75) (17). IAP75 
belongs to a complex of outer membrane proteins that function in polypeptide transport (17). 
Thus, Omp85 may play a similar role in Neisseria.
3) Omp85 may be involved in signal transduction. GenBank database search revealed 33% 
identity between Omp85 and Photorhabdus luminescens outer membrane antigen (Oma) 
(GenBank accession No AJ236920, Chatonnet-Marton, et al., unpublished data). P. luminescens 
Oma is located in a genomic region that promotes pleiotropy in response to various 
environmental conditions (9). Therefore, it is possible that Omp85 may be involved in signal 
transduction.
1-5. Research Goal, Hypothesis, and Specific Aims
The long-term goal of this work is to evaluate the vaccine potential of meningococcal Omp85. In 
this project, the ability of Omp85 to induce the generation of bactericidal antibodies was 
investigated.
Hypothesis
The hypothesis tested was that rabbit antiserum generated against the first 445 amino acids of 
meningococcal Omp85 (N44smcOmp85) specifically triggers complement-mediated killing of N. 
meningitidis and N. gonorrhoeae. The N-terminal half of Omp85 was the focus of this s tudy 
because it was previously shown that the entire Omp85 protein is difficult to express in E. coli, 
and systematically evaluating different fragments of Omp85 will allow for pinpointing of a 
putative bactericidal-elicitmg epitope.
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To test the hypothesis, the following Specific Aims were investigated:
1) DNA encoding for N4450mp85 was cloned into a hyperexpression vector.
2) Recombinant N^^^OmpSS was hyperexpressed in E. coli, then purified by affinity 
chromatography.
3) Rabbit antiserum was generated against purified recombinant N^^^OmpSS.
4) Anti- N4450mp85 rabbit serum was used in bactericidal assays against 
N. meningitidis and N. gonorrhoeae.
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Materials and Methods
2-1. Bacterial Strains
Strain Source
N. gonorrhoeae FA 19 Dr. P. Fred Sparling, University of North 
Carolina, Chapel Hill, NC
N. gonorrhoeae FA638 Dr. Keith Joiner, NIH, Bathesda, MD
N. gonorrhoeae JSl Dr. John Swanson, Rocky Mountain 
Laboratories, NIAID, NIH, Hamilton, MT
N. gonorrhoeae MS 11 LOS A Dr. John Swanson, Rocky Mountain 
Laboratories, NIAID, NIH, Hamilton, MT
N. meningitidis 8543 Dr. Richard Rest, Hahnemann School of 
Medicine, Philadelphia, PA
N. meningitidis HH Dr. Zell McGee, University of Utah, Salt Lake 
City, UT
2-2. DNA Isolation
N. meningitidis HH was grown in 3 ml gonococcal clear typing broth (GC broth, 37°C with 5% 
COi) to an ODeoonm » 1.0 . This culture, 0.25 ml, was then used to inoculate 5 ml GC broth.
This was grown to an ODeoonm = 0.4 - 0.6, then centrifuged at 3000 rpm for 10 mm. The resulting 
pellet was resuspended in 567 pi TioE, (lOmM Tris, ImM EDTA), then treated with 30 pi of 
10% SDS, 6 pi proteinase K (20 mg/ml), and 1 pi Rnase A (10 mg/ml). This was mixed and 
incubated at 37 °C for 1 hr. Phenol extraction was then performed (4), and DNA was 
resuspended in 100 pi T,oE,.
2-3. SDS-PAGE and Western blotting
Discontinuous sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed essentially as described by Laemmli (15). The protocol for Neisseria whole cell 
lysates was described by Judd (12). Separated proteins were transferred to polyvinylidine 
diflouride membranes using a Bio-Rad Trans Blot Cell. The transfer was performed in degassed 
20 mM sodium phosphate buffer, pH 8.0, for 16 hr at 450 mA. The membrane was blocked for 1
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hr in Dulbeco’s phosphate buffered saline (dPBS) containing 2% skim milk prior to an overnight 
incubation in diluted primary antibody (in dPBS). The membrane was then incubated for 1 hr in 
protein A-horseradish peroxidase (1:2500 dilution dPBS). Blots were developed in 4-chloro-i - 
naphthol and hydrogen peroxide buffered in methanol.
2-4. Genetic fusion of n44smcOmp85 to poly-histidine tag
A. Polymerase Chain Reaction (PCR)
Primers were designed to amplify bases 76-1396 of meningococcal Omp85, 25 nucleotides 
downstream of the signal peptide cleavage site (Figure 1). Primer designations and sequences 
were as follows:
5’ mOmp85 pTrcHis TOPO: 5’ CAAGACATCCGTGTCGAA 3’
3’ GC-1(.5) Omp85: 5’ GTTAGCTTCGCGAGGC 3’
Plasmid DNA containing Omp85 from N. meningitidis HH ( 17) was used as the template. Prior 
to PCR amplification, the template was linearized by treatment with the PstI restriction enzyme. 
Reactions were performed using AccuTaq^*^ LA DNA Polymerase (Sigma-AIdrich, D8045) and 
Perkin-Elmer Cetus Thermocycler Model 480. The following parameters were used:
1. 95° C 1 minute
2. 95° C 1 minute
62° C 30 seconds ^  25 cycles
72° C 1 minute _J
3. 72° C 7 minutes
Restriction enzyme analysis using ̂ cc7 and H in d i was performed on the amplified DNA to 
verify its identity (see Figure I for map of restriction sites).
B. Plasmid Construction (see Figure I for schematic diagram)
The pTrcHisTOPO TA Cloning Kit (Invitrogen, K4410-01) was used to insert PCR-amplified 
fj^^pncOmp85 into the pTrcHisTOPO plasmid. All reactions were performed according to 
manufacturer’s specifications. Transformation of the recombinant plasmid into TOP 10 One
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Shot® E. coli cells was performed according to manufacturer’s specifications then plated onto LB 
agar containing 50 pg/ml ampicillin and 0.2% glucose. Plasmid DNA was isolated from 
transformants using a QIAprep Spin Plasmid Kit (Qiagen, 27104), then analyzed by restriction 
digest to check for presence and orientation of the insert. Two sets of double digests using 
BamHI/EcoRl und Aval/EcoRI were used for the analysis (see Figure 1).
C. Subcloning is445mcOmp85 into pTrcHisB
To obtain optimal expression of the fusion protein, M4smcOmp85 was subcloned out of 
pTrcHisTOPO and into the pTrcHisB plasmid using the Xpress™ System (Invitrogen, V36020). 
Plasmid DNA consisting of pTrcHisTOPO plus N44}fncOmp85 was isolated from transformed 
TOP 10 One Shot® £. coli cells using a Midi Plasmid Purification Kit (Qiagen, 12143). BaniHI 
and EcoRl 'Next then used to excise m45fncOmp85 from pTrcHisTOPO. The resulting fragments 
were electrophoresed on a 1% agarose gel, and the excised insert was gel purified using a 
QIAquick Gel Extraction Kit (Qiagen, 28704). The excised t444snicOmp85 was then ligated into 
the BamHI and EcoRl sites of pTrcHisB using T4 DNA Ligase (New England Biolabs, Inc.). The 
resulting plasmid was designated pLGl (see Figure 1 for schematic diagram). Prior to ligation, 
pTrcHisB was treated with calf intestine alkaline phosphatase (Boehringer Mannheim) to prevent 
self-ligation. Plasmid pLGl was transformed into E. coli DH5a cells (Gibco BRL) according to 
manufacturer’s specifications. Transformants were screened for presence and orientation of the 
insert using PCR- and restriction enzyme analysis. The latter involved a single digest using AccI 
and a double digest using HindllHNhel.
2-5. Expression of fusion protein
The fusion protein was expressed according to the protocol provided by Invitrogen. Briefly, 
ToplO cells containing pLGl were grown overnight in 1 ml LB broth containing 50 pg/ml 
ampicillin and 0.2% glucose. From the overnight culture, 0.2 ml was used to inoculate 10 ml LB 
broth containing 50 pg/ml ampicillin. This was grown to an ODüoonm of approximately 0.6, at
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which point expression was induced by adding IPTG to a final concentration of 1 mM. Induction 
was allowed to proceed for 4 hours. Aliquots of cells, 1 ml, were then collected and centrifuged. 
The resulting pellets were solubalized in 100 pi SDS-PAGE sample buffer. Western blot was 
then performed as described by Judd (12) to verify that the pelleted cells expressed the fusion 
protein. Rabbit antiserum, previously generated against the first 178 amino acids of gonococcal 
Omp85 (17), was used as the primary antibody (1:500 dilution in dPBS). Protein A-horseradish 
peroxidase was used to detect the primary antibody (1:2500 dilution in dPBS).
2-6. Purification of fusion protein
Recombinant N44snacOmp85 was purified using pTrcHis Expression and Purification Kit 
(Invitrogen, K860-01). A 50 ml culture of induced cells was harvested by centrifuging at 3000 
rpm for 10 min. Cells were resuspended in 1/10 the culture volume of ice-cold 10 mM Tris- 
acetate containing 0.75 M sucrose, pH 7.8. Egg white lysozyme was added to an approximate 
final concentration of O.I mg/ml, then the cells were incubated on ice for 2 min. Cells were 
handled very gently at this point to prevent premature release of the fusion protein. Two volumes 
of ice-cold 1.5 mM EDTA were slowly added over a period of 10 min, while applying gentle 
agitation. The cells were then centrifuged at 2500 rpm for 10 min, then resuspended in 1/5 the 
culture volume of guanidinium lysis buffer. Cells were sonicated on ice (20 second bursts, 10 
second rests) for a total of 5 min. The sonicated material was then centrifuged at 13,000 rpm for 
15 min to separate out insoluble debris. The supernatant, which contained the fusion protein, was 
applied in batch mode to a ProBond™ nickel column (Invitrogen). Subsequent binding and wash 
steps were performed according to manufacturer’s specifications using low speed centrifugation. 
The fusion protein was then eluted off the column in I ml fractions. All fractions were analyzed 
by SDS-PAGE and Coomassie Brilliant Blue staining as described previously (27). Fractions 
containing purest N44smcOmp85 were pooled and dialyzed against water. Protein concentration 
was approximated using bovine serum albumin standards.
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2-7. Generation of ant:-N44smcOmp85 rabbit serum
Polyclonal rabbit serum against recombinant N445mcOmp85 was generated as described by 
Porcella (21). Prior to immunization, serum was collected from the rabbit for use as a control. 
Primary immunization, consisting of 0.5 mg purified N44smcOmp85 (in dPBS) and 0.5 ml 
Freund’s complete adjuvant, was administered subcutaneously at four sites into a New Zealand 
White rabbit (Western Oregon Rabbit Company). Two weeks later, secondary immunization, 
consisting of 0.5 mg purified N44smcOmp85 (in dPBS) and 0.5 ml Freund’s incomplete adjuvant, 
was administered subcutaneously at four sites. Intravenous boosts, consisting of 1 mg purified 
N445mcOmp85 in dPBS, were then administered weekly over a period of two months. Antibody 
titer was determined using Western blot strips containing solubalized N. gonorrheae MSI 1 
LOSA.
2-8. Enzyme-Linked Immunosorbent Assay (ELISA)
ELISA using N. gonorrhoeae MS 11 LOS A as plating antigen was performed to determine 
antibody titer and to evaluate surface reactivity of anti- N445mcOmp85 antibody. N. gonorrhoeae 
MSI 1 LOS A was grown in GC broth to an ODôoonm = 0.68, which corresponds to approximately 
5x10^ cfti/ml. Cells were pelleted, then resuspended in an equal volulme of PBS. To fix the 
cells, gluteraldehyde was added to a final concentration of 0,5%, then incubated overnight at 4°C. 
Cells were then washed three times in PBS. Plating was performed by dispensing 100 pi of 
5x10^ cfu/ml fixed cells into an Immulon 96-well plate. The plate was centrifuged at 3000 rpm 
for 15 min, then the supernatant was aspirated off. Cells were air dried onto the plate by 
incubating at 4°C overnight. Wells were blocked by adding 200 pi of 1% BSA in PBS (BSA- 
PBS), then incubating at room temperature for 2 hr with gentle agitation. Wells were washed 
three times in BSA-PBS. Primary antibody was diluted in PBS-BSA, then 100 pi was added to 
each well. This was incubated overnight at 4°C, followed by three washes with BSA-PBS. Anti- 
rabbit IgG alkaline phosphatase conjugate (Sigma, A-3687) was diluted 1:5000 in BSA-PBS, then
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100 |u,l was added per well. This was incubated for 1 hr at 4°C, followed by three washes with 
BSA-PBS. The substrate was prepared by adding 1 tablet of p-nitrophenyl phosphate (NPP) in 10 
ml of IM diethanolamine buffer. The prepared substrate, 100 pi, was then added to each well. 
Reaction was allowed to proceed for 20 min before measuring optical density of the wells at 
wavelength 405 nm using a Vmax ELISA plate reader.
2-9. Bactericidal Assay
The bactericidal assay performed was a modified version of the assay described by Cadieux (6). 
Serum was incubated at 56 °C for 45 min to eliminate intrinsic complement proteins, then filter 
sterilized by passage through a Millex-GP 0.22 pm filter (Fisher, SLOP R25 LS) that was 
previously blocked with 1% BSA in PBS. Two-fold serial dilutions of the serum were then 
prepared (1:4 to 1:1024) in Hanks’ balanced salt solution containing 1% (w/v) casein hydrolysate 
(HBSS-cas). Next, 70 pi of each serum dilution was dispensed into separate wells of a 96-well 
microtiter plate. Fresh cultures of transparent non-piliated N. gonorrhoeae, adjusted to a density 
of 8x10^ cells/ml in 31 pi HBSS-cas, were then added to each well. This was incubated for 15 
min at 37 °C with 5% CO2 . Each well then received 12.5 pi of human complement (Sigma, S- 
1764) that was preabsorbed with gluteraldehyde-fixed N. gonorrhoeae. This was incubated for 
45 min at 37 °C with 5% CO2 , after which 100 pi from each well was plated onto a GC plate. 
Plates were incubated overnight, then bactericidal endpoint was calculated.
2-10. Biotinylation and Immunoprécipitation Combination Assay 
A biotinylation assay was performed using ECL protein biotinylation module (Amersham 
Pharmacia, RPN 2202). N. gonorhoeae MSI 1 LOS A was grown in GC broth to a density of 
-5x10^ cfu/ml (OD6oonm=0.68). Cells were then washed three times in ice-cold dPBS. After the 
final wash, cells were resuspended in two-thirds the culture volume of ice-cold 40mM 
bicarbonate buffer. Biotinylation reagent was added (40 pi per ml of cells), at which point the 
cells were incubated for precisely 30 min at 4°C with gentle agitation. Cells were then washed
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three times in ice-cold dPBS. After the final wash, the pellet was resuspended in an equal volume 
of lysis buffer (250 mM NaCl; 25 mM Tris-HCl, pH 7.5; 5 mM EDTA, pH 8.0; 1% Triton-X 
100), then incubated at 4°C for 45 min with gentle agitation. The lysate was then centrifuged at 
13,000 rpm for 10 min. To 100 pi of the supernatant containing soluble biotinylated outer 
membrane proteins was added 50 mg prewashed protein A-sepharose beads (Sigma, P-3391) and 
100 pi anti-N44snficOmp85 rabbit serum that was preabsorbed with DH5a/pTrcHisB lysate. This 
mixture was incubated for 1 hr at 4 °C with gentle agitation. The beads were then washed three 
times in 1 ml dPBS. After the final wash, beads were solubalized in 100 pi of Ix solubilizing 
solution. The beads were subsequently collected by centrifugation. To visualize proteins bound 
to the beads. Western blot was performed on the supernatant as described previously (12). The 
membrane was blocked in 5% ECL blocking agent in PBS-T for 1 hr, followed by three washes 
in PBS-T. Streptavidin-horseradish peroxidase conjugate (1:1500 dilution in PBS-T) was then 
added to the membrane, and incubated at 4°C for 1 hr with gentle agitation. The membrane was 
then washed three times in PBS-T. To detect biotinylated proteins, equal volumes of ECL 
detections solutions 1 & 2 were mixed, then applied to the protein side of the membrane. This 
was incubated for precisely 1 min at room temperature without agitation. Excess detection 
reagent was then decanted, and the membrane was wrapped in Saran wrap. In a darkroom, the 
wrapped membrane was placed in an X-ray film cassette together with Hyperfilm MP 
Autoradiography Film (Amsersham Pharmacia, RPN 1677K), with the protein side of the 
membrane facing the film. The film was exposed for 90 sec, then developed immediately using 
GBX Developer (Sigma, P-7042).
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2-11. Immunoprécipitation Assay
N. gonorrhoeae MS 11 LOS A was grown in GC broth to a density of -2x1 O'* cfu/ml 
(OD6oonm=0.34). Cclls wctc then washed three times in ice-cold dPBS. To prevent cell lysis, 
cells were resuspended each time using gentle pipetting. After the final wash, cells were 
resuspended in one-fifth the culture volume of dPBS. Washed cells, 2 ml, were mixed with 1 ml 
anti-N445mcOmp85 rabbit serum that was preabsorbed with DH5a/pTrcHisB lysate. This was 
incubated for 1 hr at 4°C with gentle agitation. Cells were then gently washed twice with ice- 
cold dPBS to eliminate unbound antibodies. After the final wash, cells were resuspended in 3 ml 
of ice-cold dPBS. Prewashed protein A-sepharose beads (Sigma, P-3391), 150 mg, were then 
added to the cells and incubated for 1 hr at 4°C. The beads were then centrifuged at 1000 rpm for 
2 min, and the supernatant removed. To release antigens, the beads were vigorously resuspended 
in 3 ml of a mild lysis buffer [250 mM NaCl; 25 mM Tris-HCl, pH 7.5; 5 mM EDTA, pH 8.0;
1% (v/v) Triton-X 100], and incubated at 4°C for 30 min with gentle agitation. The beads were 
then centrifuged at 1000 rpm for 2 min, and washed in 3 ml dPBS. This was repeated for a total 
of three washes. The beads were then solubalized in 150 pi of 2x solubilizing solution, after 
which the beads were spun down and the supernatant was saved. The supernatant was loaded 
onto an SDS-PAGE gel, then analyzed via Western blot.
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Results
3-1. Genetic Fusion of N445mcOnip85 to Poly-Histidine Tag
A. Cloning N445mcOmp85 into pTrcHis-TOPO
N44$rrtcOmp85 was inserted into a hyperexpression vector containing a poly-histidme tag to allow 
for purification and characterization of the expressed protein. The pTrcHis-TOPO vector used 
allowed for efficient insertion of PCR products. Nucleotides 76-1396 of meningococcal Omp85 
were PCR-ampIified and inserted into pTrcHis-TOPO. The vector sequence immediately 
flanking the 5’ end of the insert was similar to nucleotides 64-75 of meningococcal Omp85 at the 
amino acid level (Figure 2). Thus, in total, nucleotides 64-1396 of meningococcal Omp85 were 
essentially cloned into pTrcHis-TOPO. The signal sequence of meningococcal OmpSS was 
omitted in this construct to prevent toxic accumulations of the expressed protein at the surface of 
transformed cells. Expression of the vector’s ampicillin resistance gene occurs only when an 
insert is present. Thus, all colonies that appeared on an ampicillin plate following cloning and 
transformation reactions were considered to have taken up a vector containing an insert. To 
confirm correct orientation of the insert, plasmid DNA from several colonies was analyzed using 
restriction enzymes AccI, BamHI, and EcoRl (Figure 1).
B. Subcloning \44smcOmp85 intopTrcHisB
Expression levels of N44sOmp85 in the pTrcHis-TOPO vector were not as high as expected . 
Therefore, N44sOmp85 was subcloned out of pTrcHis-TOPO and into pTrcHisB, a similar vector 
that also contains the poly-histidine tag. The insert was excised from pTrcHis-TOPO using 
EcoRJ BamHI, then ligated into pTrcHisB using corresponding restriction sites (Figure 1). 
The resulting plasmid was designated pLGl (Figure 3). Following cloning and transformation 
reactions, several colonies were screened using PCR analysis to confirm presence of the insert.
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Plasmids from colonies that contained the insert were subsequently analyzed using restriction 
enzymes AccI, Hindlll, and Nhel to confirm correct orientation (Figure 1 ).
3-2. Expression and Purification of Recombinant N445mcOmp85
Expression of recombinant N44snicOmp85 in transformed TOP 10 One Shot® E. coli cells was 
induced with IPTG. To determine optimal induction time, 1 ml samples of transformed cells 
were collected at 2 hr, 4 hr, and 16 hr post induction. Each sample was separated on a 12.5% 
SDS-PAGE gel, then analyzed by CBB staining. An induced protein of approximately 55 kDa, 
which is the expected molecular mass of recombinant N44smcOmp85, was present in all samples. 
Optimal expression of the fusion protein occurred after a 16 hr induction (Figure 4). To confirm 
identity of the induced protein, each sample of transformed cells was analyzed via Western blot. 
Antibody previously generated against the first 178 amino acids of gonococcal Omp85 (anti- 
PM 04) (17) was used as a probe. Anti-PM04 reacted with a -55 kDa protein in all samples 
containing pLGl (Figure 5), indicating that the induced protein was indeed recombinant 
N44smcOmp85. A ~55 kDa band was visible in the lane containing uninduced N445mcOmp85 
clone; however, this band was not observed in the CBB-stained SDS-PAGE gel of the uninduced 
clone. Since Western blot is much more sensitive than CBB staining at detecting proteins, these 
results may indicate expression of small amounts of the recombinant protein prior to IPTG 
induction, which is not uncommon. Purification of recombinant N44smcOmp85 was performed 
using affinity chromatography; induced transformants were disrupted by sonication, then applied 
to a nickel column. The identity of the eluted protein was again confirmed by CBB staining of a 
12.5% SDS-PAGE gel, which revealed the presence of a -55 kDa protein (Figure 6). Identity of 
the eluted protein was also confirmed by Western blotting. Antibody against the Xpress™ 
epitope of the recombinant protein (Identified in Figure 3) was used to probe the blot. In 
agreement with the CBB stain, the probe also detected a protein of approximately 55 kDa 
(Figure 7).
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Figure 1. Construction of pLGl. Nucleotides 76-1396 (indicated in parentheses) of N. 
meningitidis HH Omp85 (N445mcOmp85) were PCR-amplified using the following primer pair, 
which was designed to omit the Omp85 signal peptide: 5’ mOmp85 pTreHis TOPO and 3’ GC- 
1(.5) Omp85. The PCR product (designated as a 1320 bp insert) was then ligated into pTrcHis- 
TOPO. N445incOmp85 was subsequently excised out of pTrcHis-TOPO, gel-purified, and then 
inserted into the pTrcHisB multiple cloning site (MCS) using BamHI and EcoRI restriction sites. 
The resulting plasmid, termed pLGl, was constructed so that N44snicOmp85 was directly adjacent 
to an enterokinase cleavage site (EK) and a poly-histidine tag [(Hisle], which allowed for affinity 
purification of the recombinant protein product. Plasmid LGl contained several restriction sites 
(position, relative to recombinant protein start codon, is indicated in parentheses) that were used 
to confirm presence and orientation of the insert.
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Nucleotides 64-75 o f mcOmp85
asp \ phe  i thr \ He 
G AC TTC i c d  ATC
G A T pC A  ÀCÇ CTT 
,asp \ pro  IM rJ  leu
Nucleotides 76-1396 of mcOmpSS
pTrcHis-TOPO-N445incOmp85
Figure 2. Cloning of nucleotides 64-1396 of N. meningitidis HH Omp85 into pTrcHis-TOPO. 
The inserted PCR producted (indicated by gray shading) was comprised of nucleotides 76- 
1396 of meningococcal Omp85. Vector sequence immediately flanking the N-terminal end of 
the inserted PCR product was similar, at the amino acid level, to nucleotides 64-75 of 
meningococcal Omp85; two of the four amino acid residues were conserved (indicated by 
dashed boxes) between the two sequences. Thus, nucleotides 64-1396 of meningococcal 
Omp85 were essentially cloned into pTrcHisB.
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BamH EcoRI
G GAT CCA ACC CTT CAA GAC ATC CGT GTC GAA ... GTT AGC TTC GCG AGG CAG
Multiple
CloningSite
(His)
Amp*^
p L G l
C olE l
Figure 3. Map of pLGl. Nucleotides 64-1396 of meningococcal Omp85 were inserted into 
the multiple cloning site of pTrcHisB using BamHI oxié ÆcoÆ/restriction sites. Adjacent to 
the insertion site were a poly-histidine tag (to allow for affinity purification of the expressed 
recombinant protein), and an Xpress™ epitope (to allow for detection of the recombinant 
protein using anti-Xpress antibody). Other plasmid features include an ampicillin resistance 
gene to allow for screening of transformants; ColEl -derived origin; lac' gene encoding for a 
lac repressor, which regulates the promoter; and trc promoter region for high-level inducible 
expression in E. coli.
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3-3. Generation of Anti-N445mcOmp85 Rabbit Serum
Three months following primary immunization, anti-N445mcOmp85 serum was at a titer of at least 
1:32,000, as determined by Western blot strips containing whole cell lysates of TV. gonorrhoeae 
MSI 1 LOS A. To ensure that the rabbit was not previously exposed to an environmental Omp85- 
expressing bacterial strain, serum was collected from the animal prior to the first immunization 
(normal rabbit serum). Western blot and ELISA analysis showed that normal rabbit serum did 
not react with the immunogen (Figures 8 & 9), suggesting no previous exposure to any Omp85- 
like protein. Reactivity of anti-N44;mcOmp85 serum against Omp85 was confirmed by Western 
blot analysis, in which the serum was used to probe the immunogen and various strains of 
Neisseria (Figure 10). When reacted against the immunogen and the E. coli clone expressing 
N44sOmp85, anti-N44smcOmp85 serum detected a protein of approximately 55 kDa; when reacted 
against a panel of Neisseria strains, anti-N44smcOmp85 serum detected a protein of approximately 
85 kDa. Since the expected molecular weights of N44;nicOmp85 and Omp85 are 55 kDa and 85 
kDa, respectively, these results suggest that antibody response against N445mcOmp85 was due to 
exposure to the immunogen.
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Figure 4. CBB-stained polyacrylamide gel illustrating induced expression of recombinant 
N445mcOmp85 in DH5a. Lane 1 contains uninduced clone, lane 2 contains clone following a 2 
hr induction, lane 3 contains clone following a 4 hr induction, and lane 4 contains clone 
following a 16 hr induction. Recombinant N445mcOmp85, which has an expected molecular 
mass of 55 kDa, is indicated with an arrow.
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Figure 5. Western blot illustrating expression of recombinant N443mcOmp85 in E. coli DH5a. 
Lane 1, GIBCO Benchmark prestained molecular weight marker (MWM), expressed in 
kilodaltons; lane 2, N44smcOmp85 clone induced for 16 hr; lane 3, N445mcOmp85 clone 
induced for 4 hr; lane 4, N445mcOmp85 clone induced for 2 hr; lane 5, uninduced 
N445mcOmp85 clone; lane 6, DH5a. Blot was probed with antibody against the first 173 
amino acids of gonococcal Omp85, Bound antibody was detected using horseradish 
peroxidase-protein A conjugate. Recombinant N44smcOmp85, which has an expected 
molecular weight of 55 kDa. is indicated with an arrow.
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Figure 6 Coommassie brilliant blue-stained polyacrylamide gel illustrating purified 
recombinant N445mcOmp85, which has an expected molecular weight of 55 kDa. Lane 1, 
GIBCO Benchmark prestained molecular weight marker (MWM), expressed in kilodaltons; 
lane 2, pure recombinant N445mcOmp85; lane 3, induced N44;mcOmp85 clone; lane 4, 
uninduced N445mcOmp85 clone; lane E. coli DH5a
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Figure 7. Western blot confirming identity of purified recombinant N44;mcOmp85, which has 
an expected molecular weight of 55 kDa. Blot was probed with antibody against the Xpress™ 
epitope of the recombinant protein (see figure 3 for map). Bound antibody was detected using 
anti-mouse IgG conjugated to horseradish peroxidase. Lane 1, GIBCO Benchmark prestained 
molecular weight marker (MWM), expressed in kilodaltons; lane 2, purified recombinant 
N445mcOmp85; lane 3, recombinant N44smcOmp85-expressing clone; lane 4, E. coli DH5a.
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Figure 8. Western blot depicting lack of reactivity of normal rabbit serum against various 
Omp85-expressing isolates. Lane 1, GIBCO Benchmark prestained molecular weight marker 
(MWM), expressed in kilodaltons; lane 2, pure recombinant N445mcOmp85; lane 3, 
N445mcOmp85-expressing clone; lane 4, N. meningitidis 8543 whole cell lysate; lane 5, N. 
gonorrhoeae MSI 1 LOS A whole cell lysate; E. coli DHSa.
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Reactivity of normal rabbit serum and 
anti-N445mcOmp85 against purified 
recombinant N445mcOmp85
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Figure 9. ELISA depicting reactivity of normal rabbit serum and anti-N445iïicOmp85 serum 
against Omp85. Purified recombinant N44gmcOmp85 was used as the plating antigen. Optical 
density of the wells was measured 25 min after addition of substrate.
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Figure 10. Western blot demonstrating reactivity of anti-N445mcOmp85 serum against various 
Omp85-expressing isolates. Lane 1, GIBCO Benchmark prestained molecular weight marker 
(MWM), expressed in kilodaltons; lane 2, purified recombinant N445iTicOmp85; lane 3, lysate 
of N445mcOmp85-expressing clone; lane 4, N. meningitidis 8543 whole cell lysate; lane 5, N. 
gonorrhoeae MSI 1 LOS A whole cell lysate; lane 6, E. coli DH5a lysate. Recombinant 
NM.icmcOmn85 has an exnected molecular mass of 55 kDa.
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3-4. Bactericidal Assay
The bactericidal assay was performed as described by Cadieux (6), with modifications. Human 
complement was preabsorbed with gluteraldehyde-fixed N. gonorrhoeae prior to inclusion into 
killing mixtures. This was done to remove proteins that may mediate non-specific, antibody- 
independent killing. One nonpathogenic, unencapsulated strain of N. meningitidis and four 
strains of N. gonorrhoeae were assayed for their susceptibility to a-N4 4 5 mcOmp85-mediated 
complement killing. Two-fold serial dilutions of a-N445mcOmp85 serum were prepared to allow 
for determination of killing titer, which was defined as the reciprocal of the last serum dilution 
that produced no bacterial growth. Results are shown in Tables 1-5. Table 1 shows bactericidal 
assay results for N. meningitidis 8542. This strain was comparatively sensitive to complement 
killing, as 10% complement prevented growth in all dilutions of both a-N445mcOmp85 and normal 
rabbit serum; killing mixtures in which complement was not added back resulted in growth of 
large numbers of colonies in all serum dilutions. Therefore, to allow for calculation of antibody- 
mediated killing titer, complement concentration was reduced to 5%. Anti-N44smcOmp85 serum 
produced a killing titer of approximately 8; however, no significant difference in killing titer was 
observed between anti-N44smcOmp85 and normal rabbit serum. Table 2 shows bactericidal assay 
results for N. gonorrhoeae MS 11 LOS A. Large numbers of colonies grew in all serum 
dilutions, indicating that this strain was resistant to serum killing. Bactericidal assay results for 
N. gonorrhoeae FA 19 are shown in Table 3. None of the serum dilutions hindered growth, 
indicating that this strain was also resistant to serum killing. Table 4 shows bactericidal assay 
results for N. gonorrhoeae J S l . Anti-N445mcOmp85 serum produced a killing titer of 
approximately 2; however, no significant difference in killing titer was observed between anti- 
N445rncOmp85 and normal rabbit serum. Table 5 shows bactericidal assay results for N. 
gonorrhoae FA638. Compared to other test strains, N. gonorrhoeae FA638 was especially 
sensitive to rabbit serum-mediated complement killing, as indicated by the relatively high killing
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titer for both anti-N445mcOmp85 and normal rabbit serum; serum dilutions in which complement 
was not added back did not seem to inhibit bacterial growth. An approximately two-fold 
difference in killing titer was observed between anti-N44smcOmp85 and normal rabbit serum. 
This suggests that N. gonorrhoeae FA638 is slightly susceptible to complement killing that is 
mediated by antibody against the first 445 amino acids of Omp85.
3-5. Biotinylation and Immunoprécipitation Combination Assay 
To test for surface exposure of Omp85, an immunoprécipitation assay was performed on 
gonococcal whole cells using anti-N445mcOmp85 rabbit serum. Omp85 comprises only a small 
percentage of total Neisseria outer membrane proteins, as indicated by SDS-PAGE and CBB 
staining of whole cell lysates. Therefore, to amplify any potential signal produced by antibody 
binding to Omp85, gonococcal whole cells were biotin-labeled prior to immunoprécipitation. 
ECL detection reagents failed to detect any biotinylated proteins immunoprecipitated by anti- 
N445mcOmp85 rabbit serum. Lysate of biotinylated whole cells was detected, indicating that the 
biotinylation and detection procedure was not flawed. To test for the possibility that biotin 
labeling blocked binding sites for anti-N44snicOmp85, the antiserum was used to probe 
biotinylated and unlabeled whole cells via Western blot and ELISA. The Western blot revealed 
that anti-]vj445mcOmp85 detected an -85 kDa protein fi-om unlabeled cells; anti-N44smcOmp85 
failed to detect Omp85 from biotinylated cells (Figure 11). Likewise, the ELISA showed greater 
reactivity of anti-N44stncOmp85 against unlabeled whole cells, as compared to reactivity against 
biotinylated cells. Also tested were antibody against the first 178 amino acids of gonococcal 
Omp85 (anti-PM04) and antibody against amino acids 445-798 of meningococcal Omp85 (anti- 
2(.5)mcOmp85). Both Anti-PM04 and anti-2(.5)mcOmp85 exhibited decreased reactivity 
against biotinylated gonococcal whole cells, as determined by Western blot and ELISA
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aiv445»ncOmp85
+10% C’
Normal 
rabbit 
serum 
+10% C’
aN44smcOmp85
+5% C’
Normal 
rabbit 
serum +
5% C’
a^4j5mcOmp8 
5 without C’
1 2 0 0 0 1 250
1 4 0 0 0 2 250
1 8 0 1 6 11 250
1 16 1 0 40 100 250
1 32 0 0 100 150 200
1 64 0 0 100 150 200
1 128 17 0 100 200 200
1 256 1 0 75 150 150
1 512 0 0 75 150 150
1 1024 0 1 250 150 200
Table 1: Bactericidal assay to evaluate complement-mediated killing of N. meningitidis 8542 
induced by anti-N445iricOmp85. Number of colonies counted on each plate is indicated.
aN44smcOmp85 
+10% C’
Normal rabbit 
serum +10% C’
aN445mcOmp85 
without C’
1 2 200 225 150
1 4 225 200 150
1 8 225 150 175
1 16 225 125 175
1 32 200 150 125
1 64 225 150 125
1 128 225 150 125
1 256 200 175 50
1 512 225 175 35
1 1024 225 200 22
Table 2: Bactericidal assay to evaluate complement-mediated killing of N. gonorrhoeae MSI 1 
LOS A induced by aN445mcOmp85. Number of colonies counted on each plate is indicated.
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aN44smcOmp85
+10% C’
Normal rabbit 
serum +10% C’
aN44smcOmp85 
without C’
1 2 200 200 200
1 4 200 200 200
1 8 200 200 200
1 16 200 200 200
1 32 200 200 200
1 64 200 200 200
1 128 200 200 200
1 256 200 200 200
1 512 200 200 200
1 1024 200 200 200 i
Table 3: Bactericidal assay to evaluate complement-mediated killing of N. gonorrhoeae FA19 
induced by (%N445mcOmp85. Number of colonies counted on each plate is indicated.
aN44snicOmp85 
+10% C’
Normal rabbit 
serum +10% C’
aN44smcOmp85 
without C’
1 2 2 1 75
1 4 50 75 75
1 8 50 100 75
1 16 150 100 50
1 32 200 150 75
1 64 200 200 75
1 128 200 200 75
1 256 200 150 50
1 512 270 200 50
1 1024 270 270 50
Table 4: Bactericidal assay to evaluate complement-mediated killing of A. gonorrhoeae JSl 
induced by aN445mcOmp85. Number of colonies counted on each plate is indicated.
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aN44s*ncOmp85
+10% C’
Normal rabbit 
serum +10% C’
aN44smcOmp85 
without C’
1 2 0 0 50
1 4 0 0 100
1 8 0 0 100
1 16 0 0 80
1 32 0 0 100
1 64 0 2 100
1 128 0 4 80
1 256 0 8 40
1 512 4 17 22
1 1024 14 16 75
Table 5: Bactericidal assay to evaluate complement-mediated killing of N. gonorrhoeae FA638 
induced by aN445mcOmp85. Number of colonies counted on each plate is indicated.
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Figure 11. Western blot comparing reactivity of biotinylated gonococcal cells to that of 
unlabeled gonococcal cells. Anti-N445mcOmp85 serum was used as the probe. Lane 1, 
GIBCO Benchmark prestained molecular weight marker (MWM), expressed in kilodaltons; 
lane 2, unlabeled N. gonorrhoeae MSI 1 surface proteins; lane 2, biotinylated N. 
gonorrhoeae MSI 1 surface proteins.
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(Figure 12). These results suggest that biotm labeling whole cells severely hinders binding of 
anti- N445mcOmp85.
3-6. Immunoprécipitation
Since biotin labeling was found to prevent binding of anti- N44smcOmp85 to whole cells, an 
immunoprécipitation experiment was performed on unlabeled cells to assay surface exposure of 
Omp85. Whole cells were incubated with anti-N44snicOmp85 serum for 1 hr, at which point the 
cells were washed to eliminate unbound antibodies. The cells were then incubated with protein 
A-sepharose beads for 1 hr, followed by addition of a mild lysis buffer to release antigen- 
antibody complexes from the cell membrane. The beads were subsequently washed. Proteins 
bound to the beads were visualized by solubilizing the beads in SDS-PAGE buffer, then 
analyzing the solute via Western blot. Probing the blot with anti- N44smcOmp85 revealed a band 
of ~85 kDa (Figure 13). The intensity of the ~85 kDa band increased when the same number of 
cells were sonicated prior to immunoprécipitation. This was expected, since disrupting the 
membrane would increase the number of epitopes exposed. An -85 kDa protein was not detected 
from the sepharose beads when whole cells were immunoprecipitated with either normal rabbit 
serum or dPBS, indicating that the -85 kDa protein was immunoprecipitated specifically by anti- 
N445mcOmp85 serum. The multiple bands that appeared below the 52.5 kDa molecular weight 
marker resulted from protein A being solubalized off the sepharose beads, since protein A- 
sepharose beads, on their own, produced the same banding pattern.
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Comparison of reactivities of 
biotinylated- vs. unlabelled 
gonococcal cells against various 
rabbit antisera
Q 0.15
□  Biotinylated 
gonococcal 
surface proteins 
■  Unlabelled 
gonococcal 
surface proteins
Rabbit antiserum
Figure 12. ELISA demonstrating reactivity of various rabbit antisera against biotinylated- 
and unlabeled N. gonorrhoeae MS 11 LOS A. Biotinylated cells are depicted with blue bars; 
unlabeled cells are depicted with maroon bars. The following rabbit antisera were used to 
assay reactivity: anti-N445mcOmp85; serum raised against the first 173 amino acids of 
gonococcal Omp85 (anti-PM04); serum raised against amino acids 445-798 of 
meningococcal Omp85 (2(.5)mcOmp85); and normal rabbit serum (NRS).
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Figure 13. Western blot to visualize results of immunoprécipitation assay on 
gonococcal cells. Immunoprécipitation of gonococcal cells was performed using anti- 
N445mcOmp85 antiserum and protein A-sepharose beads. Proteins subsequently bound 
to the sepharose beads were visualized by solubilizing the sepharose beads, then 
analyzed via Western blot, using anti-N445ntcOmp85 as a probe. Lane I, GIBCO 
Benchmark prestained molecular weight marker (MWM), expressed in kilodaltons; lane 
2, N. gonorrhoeae MSI 1 LOS A whole cells immunoprecipitated with anti- 
N445mcOmp85; lane 3, N. gonorrhoeae MSI 1 LOS A that was sonicated prior to 
immunoprécipitation with anti-N445nicOmp85; lane 4, N. gonorrhoeae MSI 1 LOS A 
whole cells immunoprecipitated with normal rabbit serum (NRS); lane 5, N. 
gonorrhoeae MSI I LOS A whole cells immunonrecioitated with PBS.
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Discussion
Pathogenic strains of Neisseria infect up to 250 million people worldwide annually (I- 
3,5,28). N. meningitidis causes fulminant meningococcal sepsis and meningococcal meningitis, 
which can have mortality rates of up to 80% and 5%, respectively (28). N. gonorrhoeae is the 
causative agent of gonorrhea, a leading cause of urethritis, cervicitis, and pelvic inflammatory 
disease in the United States. Early diagnosis of these diseases is often difficult; early symptoms 
of meningococcal disease are very similar to those of viral and other bacterial diseases, while 
detection of gonococcal infection is often hindered by the fact that up to 40% of infected men and 
80% of infected women are asymptomatic for disease (23). Consequently, initiation of treatment 
often does not occur until later during infection, resulting in decreased effectiveness of the 
treatment and increased opportunity for unidentified carriers to spread the disease. Therefore, 
disease prevention would most likely be the most effective cure. Unfortunately, the current 
vaccine against N. meningitidis has limited effectiveness, and there is no vaccine available against 
N. gonorrhoeae.
The hypothesis tested here was that rabbit antiserum generated against the first 445 
amino acids of a meningococcal 85 kilodalton (kDa) outer membrane protein (Omp85) promotes 
specific complement-mediated killing of N. meningitidis and N. gonorrhoeae. Omp85 is a 
potential vaccine candidate since it is universally expressed by Neisseria, and its expression is 
highly conserved (17). At the nucleic acid level, all strains within a species have identical 
Omp85 (17). High interspecies homology exists at the amino acid level; meningococcal Omp85 
is 95% identical and 98% similar to gonococcal Omp85 (17). In addition, Omp85 homologues in 
Haemophilus influenzae and Pasteurella multocida were shown to induce protective immunity m 
rats (8,16,18,26). Therefore, antibodies against Omp85 could potentially confer protection 
against all strains of both N. meningitidis and N. gonorrhoeae. Evaluating the bactericidal
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activity of serum against the first 445 amino acids of meningococcal Omp85 {anti-N445mcOmp85 ) 
was one approach to assay the vaccine potential of OmpSS. The N-terminal half of Omp85 was 
focused upon here since it was previously shown that the entire molecule is difficult to express in 
E. coli. In addition, systematic evaluation of different OmpSS fragments would allow for 
pinpointing of a putative bactericidal-eliciting epitope.
To purify adequate quantities of N4 4 5mcOmp8 S for rabbit immunization, DNA encoding 
for N4 4 5mcOmp8 S, minus the signal sequence, was cloned into a hyperexpression vector. The 
pTrcHis-TOPO® vector was used, which was designed to allow for insertion of PCR-amplified 
products. This vector system included the following features: poly-histidine tag to allow for 
affinity purification of the recombinant protein via a nickel column; trc promoter region for high- 
level inducible expression in E. coli; lac operator binding site for the lac repressor; la c f  gene 
encoding for the lac repressor, which regulates the promoter; ampicillin resistance gene to allow 
for selection of transformants; origin derived from pBR322, a commonly used E. coli cloning 
vector; and an Xpress^^ epitope for detection of the recombinant protein. Plasmid DNA from the 
resulting transformants were analyzed using restriction enzymes AccI, BamHI, and EcoRI to 
confirm correct orientation o f the insert. Expression of recombinant N44smcOmp85 was induced 
with 1 mM IPTG, which prevents binding of the lac repressor to its corresponding operator. 
Subsequent SDS-PAGE and CBB stain analysis revealed that expression levels were not as high 
as expected. This may have been due to toxicity of the expressed recombinant protein to E. coli, 
or a sub-optimal vector system. To address the latter possibility, N4 4 5 mcOmp8 S was subcloned 
into pTrcHisB. The pTrcHisB vector differs from pTrcHis-TOPO® in that it lacks the TOPO 
cloning site, and it has a ColEl-derived origin. Otherwise, pTrcHisB retains all other features of 
pTrcHis-TOPO®. N4 4 5 mcOmp8 S was inserted into the multiple cloning site of pTrcHisB using 
E c o R I djaà 5 a m / / / (Figure I). Following the transformation reaction, plasmid DNA from 
resulting colonies was analyzed by PCR to confirm presence of the insert. Those clones that
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contained the insert were analyzed using restriction enzymes AccI, Hindlll, and M je/to confirm 
correct orientation (see Figure 1 for map of restriction sites). Analysis of recombinant 
N445mcOmp85 expression levels via SDS-PAGE and CBB staining showed increased protein 
expression as compared to that achieved in pTrcHisTOPO (Figure 4). Therefore, the 
pTrcHisTOPO vector was inefficient at expressing recombinant N44smcOmp85. Purification of 
the fusion protein was performed via affinity chromatography using a nickel column. CBB 
staining and Western blot analysis was used to confirm the identity of the purified protein as 
N445mcOmp85 (Figures 6&7).
To generate anti-N445mcOmp85 serum, rabbits were immunized with purified 
recombinant N44smcOmp85. Three months after primary immunization, anti-N445mcOmp85 serum 
was at a titer of at least 1:32,000, as determined by Western blot strips containing whole cell 
lysates of N. gonorrhoeae MSI 1 LOS A. To ensure that the rabbits were not previously exposed 
to Omp85 of environmental strains, serum was collected prior to immunization (normal rabbit 
serum, NRS). Western blot analysis showed that NRS did not react to either purified 
recombinant N445mcGmp85 or Neisseria whole cell lysates (Figure 8 ). Thus, reactivity of anti- 
N445mcOmp85 was a result of exposure to the immunogen, and not by exposure to environmental 
Omp85-expressing strains. The reactivity of anti-N44smcOmp85 serum was further tested via 
Western blot against the immunogen, N445mcOmp85-expressing clone, and various Neisseria 
strains. Recombinant N445mcOmp85 has an expected molecular mass of 55 kDa; anti- 
N445mcOmp85 detected a ~55 kDa protein in the lanes containing purified recombinant 
N445mcOmp85 and the N445mcOmp85-expressing clone (Figure 10). This confirmed reactivity of 
anti-N44snicGmp85 serum against the immunogen. Anti-N44smcGmp85 detected a ~85 kDa 
protein in all lanes containing whole cell lysates of various Neisseria strains (Figure 10), 
supporting previous observations that Gmp85 is universally expressed by Neisseria.
To evaluate anti- N44$mcGmp85 serum for its ability to specifically promote complement- 
mediated killing of Neisseria, bactericidal assays were performed. Gne unencapsulated strain of
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N. meningitidis and four strains of N. gonorrhoeae were assayed for their susceptibility to 
complement-mediated killing specifically promoted by anti- X44smc0mp85 rabbit serum (Tables 
1-5). To quantify bactericidal activity, two-fold serial dilutions of the antiserum were performed 
to allow for determination of a killing titer, which was defined as the reciprocal of the last serum 
dilution that produced no bacterial growth. Various degrees of sensitivity to anti-N44imcOmp85 
serum was observed among the strains tested. However, most strains that exhibited sensitivity to 
anti-N445mcOmp85 serum were equally sensitive to NRS, indicating that killing was a result of 
serum components other than anti- N44snicOmp85 antibodies. N. meningitidis 8543 was unable to 
grow in any serum dilution containing 10% human complement. This agreed with previous work, 
which showed that unencapsulated meningococcal strains are much more sensitive to normal 
human serum (NHS) as compared to encapsulated strains; all unencapsulated, non-sialylated 
strains of N. meningitidis showed some degree of serum sensitivity to 10% NHS (22). Therefore, 
to determine killing titer of anti-N445mcOmp85 rabbit serum against N. meningitidis 8543, 
complement concentration was reduced to 5%. This resulted in a killing titer of approximately 4 
(Table 1). However, NRS also produced a killing titer of approximately 4, indicating that killing 
observed with this meningococcal strain was not due to anti- N445mcOmp85 antibodies.
N. gonorrhoeae MS 11 LOS A was resistant to all dilutions of anti- N445mcOmp85 serum 
and NRS.
N. gonorrhoeae FA19 was also resistant to all dilutions of anti-N445mcOmp85 and NRS. 
Resistance to NRS killing observed here agrees with previous work by Pettit et al. (20), which 
demonstrated that N. gonorrhoeae FA19 exhibited >50% survival in 25% pooled NHS. This 
particular gonococcal strain was isolated from a patient with disseminated gonococcal infection 
(DGI). Since DGI strains tend to be more serum resistant as compared to strains from 
uncomplicated gonococcal infections (20), NRS resistance exhibited by N. gonorrhoeae FA 19 
agreed with previous results.
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N. gonorrhoeae JSl was sensitive to killing by anti-N445mcOmp85, producing a killing 
titer o f approximately 2. However, NRS also produced a killing titer of approximately 2, 
suggesting that the killing induced by anti-N44snicOmp85 was non-specific. Pettit et al. (20) 
found N. gonorrhoeae JSl to be resistant to killing by 25% pooled normal serum. This 
discrepancy in sensitivities to normal serum may be due to differing serum components between 
NRS and NHS. N. gonorrhoeae JSl was isolated from a patient with uncomplicated gonococcal 
infection; since such strains are often sensitive to serum killing (20), the observation that JSl is 
sensitive to NRS is likely not anomalous.
TV. gonorrhoeae FA638 was sensitive to killing by anti-N445mcOmp85, producing a killing 
titer of 512. This was approximately twice the killing titer produced by NRS, suggesting that 
antibodies against N44smcOmp85 promoted some degree of complement-mediated killing against 
this strain. TV. gonorrhoeae FA638 was previously shown to have truncated lipooligosaccharide 
(LOS) (20). Thus, it is possible that this strain’s sensitivity to anti-\44smcOmp85-specific killing 
was due to increased surface exposure of Omp85 epitopes. It may also be possible that TV. 
gonorrhoeae FA638 expressed more Omp85 than other strains, although such differences in outer 
membrane protein expression levels between strains have never been addressed.
The strains tested here exhibited varying degrees of sensitivity to NRS killing. Several 
factors contributing to serum sensitivity in Neisseria have been previously described. 
Cytidinemonophospho-N-acetylneuramic acid (CMP-NANA), the nucleotide sugar of sialic acid, 
confers serum resistance upon binding to LOS (22). Both meningococci and gonococci are 
capable of being sialylated; however, only meningococci are capable of endogenous LOS 
sialylation (22). Human secretions serve as the source of sialic acid for most resistant gonococcal 
strains; therefore serum resistance is often lost after repeated subcultures (2 2 ). Sialylated 
gonococci resist serum killing by exhibiting increased binding to factor H (22). which regulates 
the complement cascade by inactivating surface-bound C3b. Binding of factor H to surface- 
bound C3b was demonstrated using non-sialylated gonococci, which bound factor H only if the
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cells were previously incubated in NHS; non-sialylated gonococci that were previously incubated 
in heat-inactivated serum did not bind factor H (22). Since heating serum causes the inactivation 
of complement proteins, these observations indicated that factor H binds non-sialylated cells only 
if they were previously coated with C3b.
Porin (For) is another factor that contributes to serum resistance. Gonococci express one 
of two porin isoforms. For A or For B (22). Strains that express For A are often associated with 
DGI, which in turn are associated with serum resistance (22). Gonococci that express For B are 
more closely associated with local urogenital disease (2 2 ), and tend to be more serum sensitive. 
Therefore, For A expression is often indicative of a serum resistant phenotype. Serum resistance 
in For A-expressing strains may be due to the fact that factor H preferentially binds For A over 
For B (22). As a result. For A strains have less surface-bound C3b, which is inactivated by factor
H. The role of For A-factor H binding in conferring serum resistance was studied using 
monoclonal antibodies against the fifth loop of For A (a-sLFor A), which serves as the binding 
site for factor H. Serum resistant strains that were incubated with a-stPor A antibodies were 
subsequently rendered sensitive to NHS (22). Thus, binding of factor H to For A plays a role in 
conferring serum resistance in gonococci.
Serum resistance associated with For A-expressing strains may also be partially attributed 
to the fact that C4b-binding protein (C4bp) preferentially binds For A over For B (22). C4bp is a 
fluid-phase regulator of the classical pathway, and is involved in mediating inactivation of C4b. 
Since C4b is required for the formation of C3 convertase in the classical pathway, C4b 
inactivation results in serum resistance by preventing accumulation of C3b.
In meningococci, encapsulation and sialylation are the two main factors contributing to 
serum resistance and virulence. It was previously shown that strains isolated from patients with 
invasive meningococcal disease possess both a capsule and sialylated LOS (22). In addition, only 
strains possessing both a capsule and sialylated LOS were capable of causing bacteremia in
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infanat rats (22). All encapsulated strains exhibited at least 20% survival in 10% NHS (22), while 
non-encapsulated, non-sialylated strains showed some degree of sensitivity to the same 
concentration of NHS (22). Encapsulation and sialylation have an additive effect on conferring 
serum resistance, since encapsulated, sialylated strains were more serum resistant than 
encapsulated, non-sialylated strains (22). Furthermore, exogenous addition of CMP-NANA to 
encapsulated strains increased serum resistance in encapsulated, non-sialylated strains (2 2 ). 
Encapsulation likely confers serum resistance by masking outer membrane binding sites for C4 
and C5b (22). 04  participates in the classical pathway by serving as the precursor to C4b, which 
is one of the components of the 03 convertase. 05b binds cell surfaces, and provides a 
foundation for the formation of membrane attack complex (MAO). Thus, serum resistance in 
meningococci results primary from thwarting MAC formation on the cell surface. This is in 
contrast to gonococci, which resist serum primarily by the prevention of 03b deposition on the 
cell surface.
Previous studies showed that bactericidal activity of antibodies against major Neisserial 
surface antigens is affected by sialylation (7). Antibodies against LOS and Por are less 
bactericidal to sialylated cells, as compared to non-sialylated cells (7). Therefore, sialylation may 
also prevent bactericidal activity of antibodies against Omp85.
In this project, 4 out o f  the 5 Neisseria strains assayed were not sensitive to complement- 
mediated killing that was specifically promoted by anti-N445nicOmp85 rabbit serum. One strain 
showed only slight sensitivity to anti-N44smcOmp85-mediated complement killing; there was only 
an approximately two-fold difference in killing titer between anti-N445mcOmp85 and NRS 
(Table). The inability o f  anti-N445mcOmp85 rabbit serum to generate a strong, specific 
bactericidal response may be attributed to any o f  the factors, described above, that confer serum 
resistance upon Neisseria. It is also likely that the paucity o f  Omp85 m olecules on the cell 
surface may be a contributing factor preventing anti-N44;mcOmp85 serum from exhibiting specific 
bactericidal activity. Quantifiable CBB staining o f  Neisseria w hole cell lysates indicated that
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
47
Omp85 comprises only a minute percentage of total outer membrane proteins. This would hinder 
anti-N445mcOmp85-mediated complement killing by the classical pathway, since it drastically 
decreases the chance that two Omp85 molecules would be in close enough proximity to allow for 
cross-linking by IgG. The pentameric nature of IgM would allow it to cross-link a single Omp85 
molecule, and thus potentially initiate the classical pathway; however, because the high titer 
serum used in these bactericidal assays was collected after several months of immunization, the 
vast majority of immunoglobulins had already experienced a class-switch to the IgG isotype.
Thus, it might be difficult for Omp85 to elicit bactericidal antibodies. Previous work showed that 
Neisseria are not susceptible to antibody-independent complement killing via the alternative 
pathway (22). This may explain the complete inability of anti-N445mcOmp85 rabbit serum to 
produce killing in some of the strains tested here.
To discount the possibility that anti-N44smcOmp85 serum did not exhibit bactericidal 
activity due to lack of Omp85 surface exposure, immunoprécipitation assays were performed on 
biotinylated gonococcal whole cells. Cells were biotinylated prior to immunoprécipitation for the 
purpose of amplifying any potential signal, by treatment with streptavidin-peroxidase conjugate, 
that may result from immunoprécipitation by anti-N445mcOmp85 serum. Signal amplification 
was desired since Omp85 molecules appeared to be sparse in the outer membrane; thus, anti- 
N445mcOmp85 antibodies likely would not immunoprecipitate sufficient quantities of Omp85 
molecules to allow for detection without signal amplification. Biotinylated whole cells were 
treated with a mild lysis buffer to release antigens. The lysed cells were then incubated with 
protein A-sepharose beads and anti- N44smcOmp85 serum to precipitate out any labeled Omp85 
molecules. The sepharose beads were subsequently washed. To determine if the beads had 
bound any biotin-labeled Omp85 molecules, the beads were solubalized, separated on SDS- 
PAGE gel, and then transferred to a PVDF membrane. To detect the presence of any biotin- 
labeled proteins, the membrane was incubated with streptavidin-peroxidase conjugate, then 
developed on autoradiography film. This procedure failed to detect any 85 kDa proteins, which
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indicated that anti- N44smcOmp85 serum was unable to bind epitopes on biotin-labelled whole 
cells. This suggested that the epitope recognized by anti- N445mcOmp85 was not surface exposed; 
alternatively, the epitope may have been surface exposed, but steric hindrance caused by biotin 
labeling may have prevented binding of anti- N44snicOmp85 antibodies. To test the latter 
possibility, biotinylated- and unlabeled gonococci were analyzed by Western blotting, using anti- 
N445mcOmp85 serum as a probe. No bands were detected in the lane containing biotinylated 
cells, while an 85 kDa band was detected in the lane containing unlabeled cells (Figure 11). 
Similar results were observed via ELISA: biotinylated cells produced a diminished signal, as 
compared to unlabeled cells (Figure 12). Biotinylation also hindered binding of antibodies 
against the first 173 amino acids of gonococcal Omp85 (anti-PM04) and antibodies against 
amino acids 445-798 of meningococcal Omp85 (anti-2(.5)mcOmp85) (Figure 12). Collectively, 
these results suggested that biotinylation sterically hindered antibody binding to the majority of 
Omp85 epitopes. This indirectly pointed to the surface-exposed nature of Omp85. Because 
biotinylation exclusively labeled surface-exposed proteins of whole cells, and biotinylation 
hindered antibody binding to Omp85, it may be deduced that Omp85 is a surface-exposed 
molecule.
To obtain more direct evidence of Omp85 surface exposure, an immunoprécipitation 
experiment was performed on unlabeled gonococcal whole cells. Whole cells were incubated 
with anti-N44smcOmp85 serum, after which unbound antibodies were washed away. The cells 
were then incubated with protein A-sepharose beads, followed by treatment with a mild lysis 
buffer to release antigens. The beads were then washed. To determine if the beads had bound 
any Omp85 molecules, the beads were solubalized, then analyzed by Western blot, using anti- 
N445mcOmp85 serum as a probe. This resulted in detection of an -85 kDa protein (Figure 13). A 
much more intense 85 kDa band was detected when the cells were sonicated prior to 
immunoprécipitation. This indicated that many Omp85 surface epitopes are inaecessible to 
antibodies due to a transmembrane or intracellular location, or due to masking by LOS. The
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increased signal caused by sonication also suggests that immunoprécipitation of Omp85 from 
whole cells was due to surface exposure of Omp85, rather than release of Omp85 from autolyzed 
cells.
Taken together, these results indicated that the Omp85 epitope recognized by anti- 
N445mcOmp85 serum is surface-exposed. This agrees with previous observations suggesting that 
Omp85 is an outer membrane protein. These observations include the presence of a signal 
peptide (29) and a C-terminal phenylalanine (25), a 10 amino acid C-terminal motif indicative of 
outer membrane proteins (25), and reactivity of anti-Omp85 antibodies against isolated 
gonococcal outer membranes (Quick and Judd, see Figure 14). Therefore, anti- N445mcOmp85 
serum was not prevented from exhibiting strong bactericidal activity due to lack of Omp85 
surface exposure. More likely, other factors contributed to the lack of bactericidal activity of 
anti-N44smcOmp85. These include the scarcity of Omp85 in the outer membrane, which may 
have prevented antigen cross-linking by antibody, and therefore thwarted initiation of the 
complement cascade via the classical pathway. It is also possible that the nature of the 
N44smcOmp85 antigen and the method used to immunize the rabbit prevented a predominant IgG3 
response, which is the subclass of IgG most effective at activating complement (10). It was 
previously shown that variations in LOS phenotype altered surface-exposure of other Neisseria 
outer membrane proteins (14). Therefore, it is possible that the lack of anti-N445mcOmp85 
bactericidal activity was due to an outer membrane protein-masking LOS phenotype expressed by 
the strains tested.
Despite the lack of bactencidal activity exhibited by anti- N445mcOmp85 serum, Omp85 is 
still a promising vaccine candidate. Since the antiserum studied in this project was raised against 
the N-terminal half of Omp85, it may be possible that epitopes located in the C-terminal half 
elicit bactericidal antibodies. Since the function of Omp85 has yet to be determined, it is also 
possible that antibodies against Omp85 may hinder an essential function or block cell adhesion.
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Figure 14 (Courtesy of Quick and Judd). Cellular location of Omp85 by Western blot 
analysis. Lysates of whole cels (WC), cytoplasm, isolated inner membranes (IM), periplasm 
and isolated outer membranes (OM) of Neisseria gonorrhoeae MSI 1 LOS A separated in a 
12.5% SDS-PAGE gel, blotted and probed with anti serum raised to the first 178 amino acids 
of Omp85 (antl-Omp85 serum). The Omp85 is identified. Molecular mass markers (MW), 
expressed in kilodaltons (k), were GIBCO Benchmark prestained markers. These results 
indicated that Omp85 was found only in whole cells and isolated outer membranes, 
confirming that Omp85 is an outer membrane protein.
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The vaccine potential of Omp85 is further implicated by its universal and conservative expression 
in all pathogenic Neiseria. Furthermore, Omp85 homologues m Haemophilus influenzae and 
Pasteurella multocida were shown to induce protective immunity in rats (8,16,18,26). Thus, 
further studies examining the vaccine potential of Omp85 are warranted.
In summary, anti-N44snicOmp85 rabbit serum did not exhibit specific bactericidal activity 
against 4 of 5 Neisseria strains. N. gonorrhoeae FA638 was slightly susceptible to anti- 
N4 4 5 mcOmp8 5-mediated complement killing; the killing titer produced by anti-N445mcOmp85 
against FA638 was approximately twice that produced by NRS. The slight sensitivity of FA638 
to anti-N445mcOmp85 killing may be attributed to truncated LOS (20), which may allow for 
greater surface exposure of the Omp85 molecule. Alternatively, this strain may express more 
Omp85 as compared to other Neisseria strains. To determine if bactericidal activity of anti- 
N445mcOmp85 was hampered due to lack of surface exposure of the corresponding epitope, 
immunoprécipitation assays were performed on gonococcal whole cells using anti- N445mcOmp85 
serum. Results from these experiments indicated that the epitope recognized by anti- 
N44smcOmp85 was indeed surface-exposed. Therefore, the lack of specific bactencidal activity 
exhibited by anti- N44smcOmp85 was more likely a consequence of other factors. These include 
the low abundance of Omp85 molecules on the outer membrane, which would decrease the 
likelihood of antibody cross-linking to two adjacent antigens, thus preventing initiation of the 
classical complement pathway. It is also possible that the nature of the N44smcOmp85 antigen and 
the method of immunization prevented a sufficient IgG3 response, thus hindering complement 
activation. LOS phenotype of the test strains may have also played a role, since previous work 
showed that variations in LOS may mask surface exposure of other Neisseria outer membrane 
proteins (14).
Although anti-N44smcOmp85 serum lacked bactericidal activity, Omp85 is still an 
attractive vaccine candidate. Unlike most previous Neisseria outer membrane protein vaccine
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candidates, Omp85 is universally and conservatively expressed by Neisseria. Moreover, Omp85 
homologues in Haemophilus influenzae and Pasteurella multocida were shown to induce 
protective immunity in rats (8,16,18,26); therefore, antibody binding to Omp85 may disrupt some 
essential function, or may prevent cell adhesion. In addition, since the anti serum used in this 
project was raised against the N-terminal half of Omp85, it may be possible that epitopes in the 
C-terminal half of the molecule may elicit generation of bactericidal antibodies. Thus, further 
studies examining the function of Omp85 and the ability of anti-Omp85 antibodies to hinder 
pathogenicity of Neisseria warranted.
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